Zynex Inc. (OTCMKTS:ZYXI)’s share price traded up 5.2% on Wednesday . The stock traded as high as $8.70 and last traded at $8.65. 212,383 shares changed hands during mid-day trading, an increase of 137% from the average session volume of 89,663 shares. The stock had previously closed at $8.22.
Several equities analysts have recently weighed in on the company. Zacks Investment Research raised Zynex from a “sell” rating to a “hold” rating in a research note on Thursday, May 23rd. B. Riley reaffirmed a “buy” rating on shares of Zynex in a research note on Friday, February 22nd.
The company has a market cap of $251.19 million, a price-to-earnings ratio of 39.32 and a beta of 1.05.
In related news, CEO Thomas Sandgaard sold 48,008 shares of the business’s stock in a transaction that occurred on Wednesday, March 20th. The stock was sold at an average price of $4.40, for a total transaction of $211,235.20. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Daniel J. Moorhead sold 13,750 shares of the business’s stock in a transaction that occurred on Wednesday, June 12th. The stock was sold at an average price of $8.25, for a total value of $113,437.50. The disclosure for this sale can be found here. Insiders have sold a total of 489,150 shares of company stock worth $3,098,466 over the last three months.
Institutional investors have recently added to or reduced their stakes in the stock. ExodusPoint Capital Management LP acquired a new position in shares of Zynex in the 1st quarter valued at approximately $45,000. Sigma Planning Corp acquired a new position in shares of Zynex in the 1st quarter valued at approximately $63,000. O Shaughnessy Asset Management LLC acquired a new position in shares of Zynex in the 1st quarter valued at approximately $118,000. WealthTrust Axiom LLC acquired a new position in shares of Zynex in the 1st quarter valued at approximately $132,000. Finally, Acadian Asset Management LLC acquired a new position in shares of Zynex in the 1st quarter valued at approximately $215,000. 0.05% of the stock is currently owned by hedge funds and other institutional investors.
About Zynex (OTCMKTS:ZYXI)
Zynex, Inc, a medical technology company, designs, manufactures, and markets electrotherapy medical devices used for pain management and rehabilitation. Its products include NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation device; NeuroMove, an electromyography triggered electrical stimulation device; and InWave, an electrical stimulation product for the treatment of female urinary incontinence.
Further Reading: Day Trading – Risk Worth the Reward?
Receive News & Ratings for Zynex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynex and related companies with MarketBeat.com's FREE daily email newsletter.